First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.
about
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association studyClinical significance of ERCC1, RRM1 and TS in non-small cell lung cancerA review of clinical practice guidelines for lung cancerPositron emission tomography to assess hypoxia and perfusion in lung cancerBlocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsA trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerNF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy targetNovel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibitionComparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerSecretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.Pattern of use of radiotherapy for lung cancer: a descriptive study.Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemComparing effectiveness with efficacy: outcomes of palliative chemotherapy for non-small-cell lung cancer in routine practice.Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study GroupIn Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic ModelQuality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trialsPercutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLCPrevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes.Deuterium depleted water effects on survival of lung cancer patients and expression of Kras, Bcl2, and Myc genes in mouse lung.PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer.Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapyRET fusion genes in Korean non-small cell lung cancer.Effectiveness of palliative care for non-small cell lung cancer.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.Personalized medicine in oncology: tailoring the right drug to the right patient.Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature.Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update.The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines.PET in the management of locally advanced and metastatic NSCLC.
P2860
Q21261276-CA7496FD-DEDA-4234-8B93-5659B21766F6Q26830488-2E2F649B-D57D-4D6D-A570-FB26A3FF3068Q26999236-0BA15D28-D4B1-4FD6-A2E5-7648CE4C7E92Q27026940-86C3C449-B48F-4638-9285-7E1F17D5A9E0Q27852078-C6A707D8-D6E7-47A6-85DC-F0CF0169087CQ28079705-0F61FB62-1C82-494E-A009-E755B207FCE2Q28487847-90531C6D-DD6A-435A-9444-FFE3C7FC03FAQ28611413-6A5C952A-3D6F-44BD-8A35-1A5E1F4F74B4Q28822272-719378C3-4E3B-4B87-AD83-E63D4897D54EQ33414080-436D342D-1673-47D2-9326-489D6E2EAC6DQ33426486-1306A4F0-0896-4CBF-B519-42733EB4EE03Q33435610-EA0DCC74-D020-407C-9B32-88B8FBE29F39Q33689021-BF4988C6-EF81-4CC7-BA16-6E367A240DABQ34000586-5B3E294F-E6AF-451F-AEE8-B0F0483FDAE5Q34112596-B100C550-9628-44A2-9868-2D1C43D3C126Q34267397-43FBF18F-042A-43E5-AF3D-4E79CED15409Q34608597-1896BB40-B121-461A-B861-A76B5CBA038EQ35714504-877CBCE3-8AB4-43DD-AB39-450BE977E776Q36040619-45AB7711-FBED-4CCB-844D-6819D8EE4835Q36117206-F9574213-D28A-455B-B31E-4FDB9F33BD07Q36140933-F3A3E1D9-2366-4D92-BC62-1DB1AE5A7371Q36224556-A6E52275-AE97-4612-8F59-01CE58037081Q36267763-59B9FE02-B8DE-433E-95F9-EF70EA0A24FFQ36682970-0E8E621D-B4C7-44F6-9F86-FCBB69B0EBB1Q36733643-237D89BD-CCF2-4155-8138-28F524C7BD30Q36903206-7A8E94E7-6A04-4B92-BDCC-23921C3C01ADQ36996781-04846725-1CB7-41E2-896E-5416E922DEE7Q36998991-517B00C5-E451-4448-950D-53AA54570778Q37225929-F51993A4-4D3B-41FF-B743-37910F19290EQ37288002-DDC34F9C-D3C7-457B-B57B-E9A25B47C27AQ37634419-9C09C650-1D6D-4B28-8EE4-3BF05ADBB70FQ37718808-2D5F1655-6B60-4458-9333-81B26A6C6213Q37779306-0E51FF66-3051-4E5F-9F93-DC5789A52AE6Q37966692-7985C749-8D8A-467C-B710-1B230E8065F5Q37989844-62C2BC4C-5B5D-4137-B208-FD2A5C889C33Q38027080-C2C1C214-DDE8-423E-B010-F1D648269167Q38062459-C23FF10C-DF43-4483-86E7-38B3F41A7FC3Q38199478-81D0F547-C726-4647-A74D-9C59590CA16CQ38375732-3C29FB2C-2D89-48C2-84B1-4560AA261443Q38444980-D0A4DC57-B47D-4807-A6F8-3B245D0DCE45
P2860
First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
First-line systemic chemothera ...... g cancer: a systematic review.
@en
First-line systemic chemothera ...... g cancer: a systematic review.
@nl
type
label
First-line systemic chemothera ...... g cancer: a systematic review.
@en
First-line systemic chemothera ...... g cancer: a systematic review.
@nl
prefLabel
First-line systemic chemothera ...... g cancer: a systematic review.
@en
First-line systemic chemothera ...... g cancer: a systematic review.
@nl
P2093
P1476
First-line systemic chemothera ...... g cancer: a systematic review.
@en
P2093
Christina Lacchetti
John Goffin
Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care
Peter M Ellis
William K Evans
P304
P356
10.1097/JTO.0B013E3181C6F035
P577
2010-02-01T00:00:00Z